Merck & Co., Inc. (ETR:6MK)
Germany
· Delayed Price · Currency is EUR | Market Cap | 174.30B |
| Revenue (ttm) | 61.98B |
| Net Income (ttm) | 16.53B |
| Shares Out | n/a |
| EPS (ttm) | 6.51 |
| PE Ratio | 10.54 |
| Forward PE | n/a |
| Dividend | 2.93 (4.23%) |
| Ex-Dividend Date | Mar 17, 2025 |
| Volume | 6,453 |
| Average Volume | 4,095 |
| Open | 69.60 |
| Previous Close | 69.30 |
| Day's Range | 69.30 - 70.30 |
| 52-Week Range | 67.20 - 125.60 |
| Beta | 0.42 |
| RSI | 27.37 |
| Earnings Date | Apr 24, 2025 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janu... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial numbers in USD Financial StatementsNews
Merck Stock Slumps Ahead Of Q1 Earnings: Can Bulls Find Relief In Buying Pressure?
Merck & Co Inc MRK will be reporting its first-quarter earnings on Thursday before the market opens. Wall Street expects earnings per share of $2.14 and revenue of $15.33 billion.
The Setup: Chipotle, United Rentals, Merck and Pepsi
The Investment Committee give you The Setup on some key names reporting this week.
The Setup: Chipotle, United Rentals, Merck and Pepsi
The Investment Committee give you The Setup on some key names reporting this week.
Merck Q1 Earnings Preview: What to expect?
Merck (MRK) Q1 earnings preview: Analysts expect $2.14 EPS on $15.33B revenue amid Keytruda concerns and Gardasil struggles.
BioNTech Surges On Summit's Coattails. But Can They Take On Merck?
BioNTech stock rocketed Wednesday after rival Summit Therapeutics unveiled promising results for a novel approach to lung cancer treatment.
Merck: Now A Single-Digit P/E With Double-Digit EPS Growth, Technical Support
Merck's Q4 results beat expectations, but concerns over Gardasil and Keytruda's patent expirations weighed on the stock. Read why MRK is a Buy.
Merck & Co.: Pipeline Resilience To Unlock Value
Merck is growing pharma sales and expanding margins, led by strong KEYTRUDA performance and cost discipline. Read more about MRK stock here.
US stocks are set to open lower
Major US stock indices are set a low below. Nvidia shares are back below the 100 level as concerns about global trade heighten anxiety. Shares of Netflix are higher after their earnings announcement a...
Gilead Trodelvy + Merck Keytruda combo excels in first-line breast cancer
Gilead's Trodelvy + Merck's Keytruda shows promise against PD-L1+ metastatic triple-negative breast cancer. Read more here.
LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed
The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts.
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Merck & Co Inc (MRK) Faces Class Action Lawsuit Over Alleged Misleading Statements | MRK ...
Merck & Co Inc (MRK) Faces Class Action Lawsuit Over Alleged Misleading Statements | MRK stock news
MERCK ALERT: Bragar Eagel & Squire, P.C. is Investigating Merck & Co., Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Merck & Co., Inc. (NYSE: MRK) o...
3-Stock Lunch: UnitedHealth, Eli Lilly and Merck
Courtney Garcia, Payne Capital Management senior wealth advisor, joins 'Power Lunch' to discuss stock plays for three stocks.
Microfiltration Membranes Market Research - Global Forecast to 2029 with Merck, Sartorius, and Pall Leading
Growth is driven by heightened demand for water and wastewater treatment due to water scarcity and stringent environmental regulations. Key industries like pharmaceuticals, food and beverages, and wat...
Price Over Earnings Overview: Merck & Co
In the current session, Merck & Co Inc. (NYSE: MRK) is trading at $78.17, after a 1.26% decrease. Over the past month, the stock decreased by 17.47% , and in the past year, by 37.65% . With performan...
Merck Signs Nearly $500 Million Licensing Deal With Austria-Based Cyprumed For Tablet-Based Peptide Delivery
Merck & Co Inc (NYSE: MRK) and privately held Cyprumed GmbH signed a non-exclusive license and option agreement on Tuesday to develop oral formulations of Merck's peptides using Cyprumed's drug deliv...
April 14, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against MRK
NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. (NYSE: MRK).
Tariffs on generic drugs will cause companies to stop making them: Former FDA Commissioner Gottlieb
Dr. Scott Gottlieb, former FDA Commissioner, joins 'Squawk Box' to discuss current pharmaceutical imports under investigation, moving production for branded and generic drugs elsewhere, and much more.
The Tariff Game Just Changed: 7 Blue-Chip Bargains To Buy Now
Unprecedented Opportunities: Recent market panic has created deep discounts among world-class blue-chip companies trading at 52-week lows, offering up to 100% potential returns and secure yields appro...
Levi & Korsinsky Reminds Merck Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - MRK
NEW YORK, NY / ACCESS Newswire / April 14, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws,...
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines - MRK
NEW YORK , April 14, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK). Such investors are advise...
Class Action Filed Against Merck & Co., Inc. (MRK) Seeking Recovery for Investors - Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / April 14, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws,...
Trump Says Pharmaceutical Tariffs Coming in Near Future
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporter...
MRK DEADLINE TODAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important April 14 Deadline in Securities Class Action - MRK
NEW YORK, NY / ACCESS Newswire / April 14, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE:MRK) between February 3, 2022 and ...